浙江寿仙谷医药股份有限公司2025年第二次临时股东会决议公告

Meeting Overview - The second extraordinary general meeting of shareholders was held on December 23, 2025, at the company's location in Zhejiang Province [2] - The meeting was convened by the board of directors, with the chairman, Mr. Li Mingyan, presiding over the meeting [2][3] - The meeting was witnessed by lawyers from Zhejiang Tiance Law Firm, ensuring compliance with legal and regulatory requirements [7] Attendance and Voting - A total of 9 directors were present, with 7 attending the meeting; two directors were absent due to official duties [3] - The voting process adhered to the Company Law and the company's articles of association, with all resolutions passed in accordance with the required majority [2][4] Resolutions Passed - The following proposals were approved during the meeting: 1. The 2026 annual routine related party transaction plan [4] 2. The application for a comprehensive credit limit and related guarantee matters for 2026 [4] 3. The use of temporarily idle raised funds and self-owned funds for cash management in 2026 [5] 4. The revision of the remuneration management system for directors and senior management [5] - Proposal 2 was classified as a special resolution, requiring approval from more than two-thirds of the voting rights held by shareholders present [5][6] Legal Opinion - The legal opinion provided by the witnessing lawyers confirmed that the meeting's procedures, participant qualifications, and voting processes complied with relevant laws and regulations [7]